Shareholders in specialty pharma group Meldex have called for assurances that the company will moderate its issuance of new equity to pay for acquisitions, and expressed concern about the depth of due diligence being performed on vendor companies. Their concerns are expected to take centre stage at the company's annual meeting today, ahead of which one of the company's non-executives has resigned.
subscriber-only content
visible-status-Subscription-Only story-url-Meldex_news_230508.xml
